These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 20221888)

  • 1. Intracellular protein binding patterns of the anticancer ruthenium drugs KP1019 and KP1339.
    Heffeter P; Böck K; Atil B; Reza Hoda MA; Körner W; Bartel C; Jungwirth U; Keppler BK; Micksche M; Berger W; Koellensperger G
    J Biol Inorg Chem; 2010 Jun; 15(5):737-48. PubMed ID: 20221888
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of the binding sites of the anticancer ruthenium(III) complexes KP1019 and KP1339 on human serum albumin via competition studies.
    Dömötör O; Hartinger CG; Bytzek AK; Kiss T; Keppler BK; Enyedy EA
    J Biol Inorg Chem; 2013 Jan; 18(1):9-17. PubMed ID: 23076343
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influence of ascorbic acid on the activity of the investigational anticancer drug KP1019.
    Bartel C; Egger AE; Jakupec MA; Heffeter P; Galanski MS; Berger W; Keppler BK
    J Biol Inorg Chem; 2011 Dec; 16(8):1205-15. PubMed ID: 21706338
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Platinum group metallodrug-protein binding studies by capillary electrophoresis - inductively coupled plasma-mass spectrometry: a further insight into the reactivity of a novel antitumor ruthenium(III) complex toward human serum proteins.
    Polec-Pawlak K; Abramski JK; Semenova O; Hartinger CG; Timerbaev AR; Keppler BK; Jarosz M
    Electrophoresis; 2006 Mar; 27(5-6):1128-35. PubMed ID: 16440400
    [TBL] [Abstract][Full Text] [Related]  

  • 5. LC- and CZE-ICP-MS approaches for the in vivo analysis of the anticancer drug candidate sodium trans-[tetrachloridobis(1H-indazole)ruthenate(III)] (KP1339) in mouse plasma.
    Bytzek AK; Boeck K; Hermann G; Hann S; Keppler BK; Hartinger CG; Koellensperger G
    Metallomics; 2011 Oct; 3(10):1049-55. PubMed ID: 21935553
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cellular uptake and subcellular distribution of ruthenium-based metallodrugs under clinical investigation versus cisplatin.
    Groessl M; Zava O; Dyson PJ
    Metallomics; 2011 Jun; 3(6):591-9. PubMed ID: 21399784
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Deceptively Similar Ruthenium(III) Drug Candidates KP1019 and NAMI-A Have Different Actions. What Did We Learn in the Past 30 Years?
    Alessio E; Messori L
    Met Ions Life Sci; 2018 Feb; 18():. PubMed ID: 29394024
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Heterocyclic complexes of ruthenium(III) induce apoptosis in colorectal carcinoma cells.
    Kapitza S; Pongratz M; Jakupec MA; Heffeter P; Berger W; Lackinger L; Keppler BK; Marian B
    J Cancer Res Clin Oncol; 2005 Feb; 131(2):101-10. PubMed ID: 15503135
    [TBL] [Abstract][Full Text] [Related]  

  • 9. cis-Tetrachlorido-bis(indazole)osmium(iv) and its osmium(iii) analogues: paving the way towards the cis-isomer of the ruthenium anticancer drugs KP1019 and/or NKP1339.
    Büchel GE; Kossatz S; Sadique A; Rapta P; Zalibera M; Bucinsky L; Komorovsky S; Telser J; Eppinger J; Reiner T; Arion VB
    Dalton Trans; 2017 Sep; 46(35):11925-11941. PubMed ID: 28850133
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Increasing the bioavailability of Ru(III) anticancer complexes through hydrophobic albumin interactions.
    Webb MI; Wu B; Jang T; Chard RA; Wong EW; Wong MQ; Yapp DT; Walsby CJ
    Chemistry; 2013 Dec; 19(50):17031-42. PubMed ID: 24203647
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Poly(lactic acid) nanoparticles of the lead anticancer ruthenium compound KP1019 and its surfactant-mediated activation.
    Fischer B; Heffeter P; Kryeziu K; Gille L; Meier SM; Berger W; Kowol CR; Keppler BK
    Dalton Trans; 2014 Jan; 43(3):1096-104. PubMed ID: 24165902
    [TBL] [Abstract][Full Text] [Related]  

  • 12. NAMI-A and KP1019/1339, Two Iconic Ruthenium Anticancer Drug Candidates Face-to-Face: A Case Story in Medicinal Inorganic Chemistry.
    Alessio E; Messori L
    Molecules; 2019 May; 24(10):. PubMed ID: 31137659
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Elucidation of the interactions of an anticancer ruthenium complex in clinical trials with biomolecules utilizing capillary electrophoresis hyphenated to inductively coupled plasma-mass spectrometry. Short communication.
    Groessl M; Hartinger CG; Połeć-Pawlak K; Jarosz M; Dyson PJ; Keppler BK
    Chem Biodivers; 2008 Aug; 5(8):1609-1614. PubMed ID: 18729095
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anticancer ruthenium(III) complex KP1019 interferes with ATP-dependent Ca2+ translocation by sarco-endoplasmic reticulum Ca2+-ATPase (SERCA).
    Sadafi FZ; Massai L; Bartolommei G; Moncelli MR; Messori L; Tadini-Buoninsegni F
    ChemMedChem; 2014 Aug; 9(8):1660-4. PubMed ID: 24920093
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nanoformulation improves activity of the (pre)clinical anticancer ruthenium complex KP1019.
    Heffeter P; Riabtseva A; Senkiv Y; Kowol CR; Körner W; Jungwith U; Mitina N; Keppler BK; Konstantinova T; Yanchuk I; Stoika R; Zaichenko A; Berger W
    J Biomed Nanotechnol; 2014 May; 10(5):877-84. PubMed ID: 24734541
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Application of capillary electrophoresis-inductively coupled plasma mass spectrometry to comparative studying of the reactivity of antitumor ruthenium(III) complexes differing in the nature of counter-ion toward human serum proteins.
    Połeć-Pawlak K; Abramski JK; Ferenc J; Foteeva LS; Timerbaev AR; Keppler BK; Jarosz M
    J Chromatogr A; 2008 May; 1192(2):323-6. PubMed ID: 18433763
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Osmium(III) analogues of KP1019: electrochemical and chemical synthesis, spectroscopic characterization, X-ray crystallography, hydrolytic stability, and antiproliferative activity.
    Kuhn PS; Büchel GE; Jovanović KK; Filipović L; Radulović S; Rapta P; Arion VB
    Inorg Chem; 2014 Oct; 53(20):11130-9. PubMed ID: 25290960
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CZE-ICP-MS as a tool for studying the hydrolysis of ruthenium anticancer drug candidates and their reactivity towards the DNA model compound dGMP.
    Groessl M; Hartinger CG; Dyson PJ; Keppler BK
    J Inorg Biochem; 2008; 102(5-6):1060-5. PubMed ID: 18222004
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular mass spectrometry in metallodrug development: a case of mapping transferrin-mediated transformations for a ruthenium(III) anticancer drug.
    Jarosz M; Matczuk M; Pawlak K; Timerbaev AR
    Anal Chim Acta; 2014 Dec; 851():72-7. PubMed ID: 25440667
    [TBL] [Abstract][Full Text] [Related]  

  • 20. X-ray Structure Analysis of Indazolium trans-[Tetrachlorobis(1H-indazole)ruthenate(III)] (KP1019) Bound to Human Serum Albumin Reveals Two Ruthenium Binding Sites and Provides Insights into the Drug Binding Mechanism.
    Bijelic A; Theiner S; Keppler BK; Rompel A
    J Med Chem; 2016 Jun; 59(12):5894-903. PubMed ID: 27196130
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.